

# Index

- 24-hr oesophageal and intragastric pH, 455  
5-aminosalicylates, 179  
5-HT1 receptor agonism, 805  
6-mercaptopurine, 679  
6-thioguanine nucleotides, 1269  
6-thioguanine, 1269  
90 years, 1153
- Abraha, H. *see* Pereira, S.P.  
Abraham, N.S., Moayyedi, P., Daniels, B. & Veldhuyzen Van Zanten, S.J.O. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia, 631  
Achem, S.R. *see* Ward, E.M.  
Acid Suppression, 591, 655  
Acidity index, 443  
Adam, V. *see* Barkun, A.N.  
Adefovir, 25  
Adverse drug reaction, 303  
Ageing, 39  
Aguirre, T. *see* El-Serag, H.B.  
Aichbichler, B.W. *see* Wenzl, H.H.  
Aithal, G.P., Haugk, B., Das, S., Card, T., Burt, A.D. & Record, C.O. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? 391  
Alahuddin, S. *see* Kaptan, K.  
Alahuddin, S. *see* Rajendra, S.  
Albanese, A. *see* Brisinda, G.  
Alicaforsen, 281  
Aloe vera, 739  
Amantadine, 339  
Ammon, S. *see* Treiber, G.  
Amoruso, A. *see* De Francesco, V.  
Anal fissure, 481  
Andreyev, H.J.N. *see* Lindsay, J.O.  
Andrieux, C. *see* Bouhnik, Y.  
Andriulli, A. *see* Mangia, A.  
Angelico, F. *see* Angelico, M.  
Angelico, M., Cepparulo, M., Angelico, F., Francioso, S., Barlattani, A., Di Candilo, F., Della Vecchia, R., Demelia, L., De Sanctis, G., Gentile, S., Grieco, A., Parruti, G., Sabusco, G., Tarquini, L., Tosti, A. & Zaru, S. The SMIEC 1 Group. A randomized controlled trial of amantadine plus interferon- $\alpha$ 2a vs. interferon- $\alpha$ 2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon- $\alpha$ 2a monotherapy, 339  
Annibale, B. *see* Panzuto, F.  
Antibiotic, 789  
Antibiotic resistance, 1009, 1315  
Antibiotic treatment, 1315  
Antidopaminergic prokinetics, 379  
Antisense, 281  
Antro-pyloro-duodenal motility, 805  
APC gene, 1225  
Apolinario, A., Diago, M., Lo Iacono, O., Lorente, R., Pérez, C., Majano, P.L., Clemente, G. & García-Monzón, C. Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy, 551  
Apoptosis, 1225  
Appropriateness, 197  
Arden, N.K. *see* Trebble, T.M.  
Arguedas, M.R. *see* Raines, D.L.  
Armstrong, D. *see* Chiba, N.  
Armstrong, D. *see* Stanghellini, V.  
Armuzzi, A. *see* Candelli, M.  
Arterial embolization, 999, 1301  
Asacol, 1089  
Aspirin, 39, 359, 1099  
Atrophic gastritis, 107  
Austin, A.S., Mahida, Y.R., Clarke, D., Ryder, S.D. & Freeman, J.G. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis, 79  
Autoimmune liver diseases, 209  
Axon, A.T.R. Personal view: to treat or not to treat? *Helicobacter pylori* and gastro-oesophageal reflux disease – an alternative hypothesis, 253  
Azathioprine, 295, 679, 1147
- Baccini, F. *see* Panzuto, F.  
Baclofen, 1041  
Bacterial virulence factors, 219  
Baier, P. *see* Büning, C.  
Bailey, D.M. *see* Kitiyakara, T.  
Baird, A.W. *see* O'Keefe, C.  
Balsalazide, 1089  
Bane, B. *see* Miner Jr, P.  
Bardhan, K.D. *see* Stanghellini, V.  
Bardou, M. *see* Barkun, A.N.  
Barkun, A. *see* Chiba, N.  
Barkun, A.N., Herba, K., Adam, V., Kennedy, W., Fallone, C.A. & Bardou, M. High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis, 591  
Barlattani, A. *see* Angelico, M.  
Barone, M. *see* De Francesco, V.  
Bautista, J., Fullerton, H., Briseno, M., Cui, H. & Fass, R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain – a randomized, double-blind, placebo-controlled, crossover trial, 1123

- Belaiche, J. *see* Louis, E.  
 Benazzato, L. *see* Di Sabatino, A.  
 Benöhr, P. *see* Raddatz, D.  
 Benson, M.J. *see* Kang, J.Y.  
 Bentivoglio, A.R. *see* Brisinda, G.  
 Berloco, P. *see* De Francesco, V.  
 Bernstein, C.N. & Leslie, W.D. Review article: osteoporosis and inflammatory bowel disease, 941  
 Beyan, C. *see* Kaptan, K.  
 Biancone, L., Tosti, C., Geremia, A., Fina, D., Petruzzello, C., Emerenziani, S. & Pallone, F. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial, 755  
*Bifidobacterium*, 889  
 Bijkerk, C.J., Muris, J.W.M., Knottnerus, J.A., Hoes, A.W. & De Wit, N.J. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome, 245  
 Bilardi, C. *see* Zentilin, P.  
*Biliary disorders*, 209, 563, 601, 901, 1153, 1293  
 Binder, V. *see* Jess, T.  
*Biofeedback*, 829  
*Biological therapy*, 749  
*Biomarker*, 797  
 Bjorkman, D. *see* Loftus Jr, E.V.  
*Bleeding*, 1051  
 Blonska-Fajfrowska, B. *see* Mangel, A.W.  
 Bloom, S., Küllerich, S., Lassen, M.R., Forbes, A., Leiper, K., Langholz, E., Irvine, E.J., O'Morain, C., Lowson, D. & Orm, S. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis, 871  
 Blumenstein, I. *see* Schröder, O.  
 Bochow, B. *see* Büning, C.  
 Bockemühl, M. *see* Raddatz, D.  
*Bone*, 1063  
*Bone biochemical markers*, 563  
*Bone densitometry*, 563  
 Borrelli, F., Capasso, R., Russo, A. & Ernst, E. Systematic review: green tea and gastrointestinal cancer risk, 497  
*Botulinum toxin*, 695  
 Bouhnik, Y., Neut, C., Raskine, L., Michel, C., Riottot, M., Andrieux, C., Guillemot, F., Dyard, F. & Flourié, B. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation, 889  
 Bouras, E.P. *see* Ward, E.M.  
 Bradley, J. *see* Miner Jr, P.  
 Bramble, M.G. *see* Panter, S.J.  
 Branca, G. *see* Cammarota, G.  
 Brandara, F. *see* Brisinda, G.  
 Brisenio, M. *see* Bautista, J.  
 Brisinda, G., Albanese, A., Cadeddu, F., Bentivoglio, A.R., Mabisombi, A., Marniga, G. & Maria, G. Botulinum neurotoxin to treat chronic anal fissure: results of a randomized 'Botox vs. Dysport' controlled trial, 695  
 Brisinda, G., Cadeddu, F., Brandara, F., Maria, G., Halphen, M., Chaussade, S., Minić, M., Guslandi, M., Cheung, O. & Wald, A. Letters to the editors, 1131  
 Bruley Des Varannes, S. *see* Galmiche, J.P.  
 Bruley des Varannes, S. *see* Zerbib, F.  
 Brune, K. *see* Dormann, H.  
 Buch, A. *see* Sandborn, W.J.  
 Bueno De Mesquita, M. *see* Marchal, L.  
 Bühner, S. *see* Büning, C.  
 Büning, C., Genschel, J., Bühner, S., Krüger, S., Kling, K., Dignass, A., Baier, P., Bochow, B., Ockenga, J., Schmidt, H.H.-J. & Lochs, H. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation, 1073  
 Burattini, O. *see* De Francesco, V.  
 Burggraaf, J. *see* Kamerling, I.M.C.  
 Burt, A.D. *see* Aithal, G.P.  
 Buxton-Thomas, M. *see* Pereira, S.P.  
 Cadeddu, F. *see* Brisinda, G.  
*CagA*, 407  
 Calder, P.C. *see* Trebble, T.M.  
 Calvert, E.L., Whorwell, P.J. & Houghton, L.A. Inter-digestive and post-prandial antro-pyloro-duodenal motor activity in humans: effect of 5-hydroxytryptamine 1 receptor agonism, 805  
 Calvet, X. *see* Gisbert, J.P.  
*Camellia sinensis*, 497  
 Camilleri, M. *see* Cremonini, F.  
 Cammarota, G., Martino, A., Pirozzi, G., Cianci, R., Branca, G., Nista, E.C., Cazzato, A., Cannizzaro, O., Miele, L., Grieco, A., Gasbarrini, A. & Gasbarrini, G. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for *Helicobacter pylori* infection, 789  
*Cancer*, 879  
 Candelli, M. *see* Santarelli, L.  
 Candelli, M., Armuzzi, A., Nista, E.C., Fini, L., Gasbarrini, G. & Gasbarrini, A. Letter to the Editors, 243  
 Cannizzaro, O. *see* Cammarota, G.  
 Capasso, R. *see* Borrelli, F.  
 Caprai, S. *see* Sciveres, M.  
*Capsaicin*, 415  
 Capurso, G. *see* Panzuto, F.  
 Carballo, F. *see* Gisbert, J.P.  
 Card, T. *see* Aithal, G.P.  
*CARD15*, 1073  
*Case-control study*, 817  
 Cash, B.D. & Chey, W.D. Review article: irritable bowel syndrome – an evidence-based approach to diagnosis, 1235  
 Castell, D.O. *see* Tutuian, R.  
 Castle, M.Z.D., Silk, D.B.A. & Libby, G.W. Review article: the rationale for antidepressant therapy in functional gastrointestinal disorders, 969  
 Cazzato, A. *see* Cammarota, G.  
*CCK*, 601  
*Celiac disease*, 1199  
 Ceppa, P. *see* Zentilin, P.  
 Cepparulo, M. *see* Angelico, M.  
 Chan, A.O. *see* Hui, C.-K.  
 Chan, A.O.O. *see* Lam, C.-M.

- Chan, A.O.O. *see* Wong, W.M.
- Chan, A.O.O., Yuen, M.F., Lam, C.M., Fong, C.Y., Wong, B.C.Y. & Lai, C.L. Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong, 401
- Chan, F.K.L. & Graham, D.Y. Review article: prevention of non-steroidal antiinflammatory drug gastrointestinal complications – review and recommendations based on risk assessment, 1051
- Chan, H.L.-Y. *see* Wong, V.W.-S.
- Chan, S.-C. *see* Hui, C.-K.
- Chang, C.-M. *see* Ng, F.-H.
- Chang, F.-Y. *see* Huo, T.
- Chang, F.-Y. *see* Huo, T.-I.
- Chang, L. *see* Schwetz, I.
- Charles, F. *see* Zerbib, F.
- Chaussade, S. *see* Brisinda, G.
- Chayama, K. *see* Kai, H.
- Chelators, 157
- Chemokines, 551
- Chemoprotective substance, 497
- Chen, H.X. *see* Xiong, L.S.
- Chen, M.H. *see* Xiong, L.S.
- Chen, S.C. & Rex, D.K. Review article: registered nurse-administered propofol sedation for endoscopy, 147
- Chen, W.-H. *see* Ng, F.-H.
- Cheung, O. *see* Brisinda, G.
- Cheung, O. & Wald, A. Review article: the management of pelvic floor disorders, 481
- Cheung, W.W. *see* Hui, C.-K.
- Chey, W.D. *see* Cash, B.D.
- Chiang, J.-H. *see* Huo, T.
- Chiang, J.-H. *see* Huo, T.-I.
- Chiba, N., Veldhuyzen Van Zanten, S.J.O., Escobedo, S., Grace, E., Lee, J., Sinclair, P., Barkun, A., Armstrong, D. & Thomson, A.B.R. Economic evaluation of *Helicobacter pylori* eradication in the CADET-Hp randomized controlled trial of *H. pylori*-positive primary care patients with uninvestigated dyspepsia, 349
- Chinn, D.J. *see* Rubin, G.P.
- Chiu, Y.-L. *see* Freston, J.W.
- Cholecystokinin, 1261
- Cholestasis, 1293
- Chronic hepatitis B, 25
- Chronic hepatitis C, 339
- Chronic Intestinal Pseudo-Obstruction, 687
- Chronic liver disease, 715
- Chronic viral hepatitis B, 323
- Cianci, R. *see* Cammarota, G.
- Ciccocioppo, R. *see* Di Sabatino, A.
- Cipollina, L. *see* Tonini, M.
- Cirrhosis, 391, 1159
- Clarithromycin, 993, 1009
- Clarke, D. *see* Austin, A.S.
- Clemente, G. *see* Apolinario, A.
- Clinical alert, 303
- Clopidogrel, 359
- Cluster analysis, 133
- Coeliac disease, 1277
- Cohen, A.F. *see* Kamerling, I.M.C.
- Cohort study, 679
- Colitis, 167, 871
- Collin, P., Thorell, L., Kaukinen, K. & Mäki, M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? 1277
- Colombel, J.-F. *see* Louis, E.
- Colon, 765
- Colonic diverticular disease, 765
- Colonoscopy, 765
- Colorectal cancer, 1, 287
- Colquhoun, S. *see* Firpi, R.J.
- Complementary therapy, 521
- Complications, 1051
- Computer assisted signal processing, 303
- Congenital abnormalities, 679
- Constipation, 481, 889
- Copper, 157
- Corazza, G.R. *see* Di Sabatino, A.
- Corazza, G.R. *see* Tonini, M.
- Cost analysis, 349
- Cost-benefit analysis, 1247
- Cost-effectiveness, 349, 591
- Cost-effectiveness analysis, 571, 1199
- Cotler, S.J. *see* Jensen, D.M.
- Courtney, E.D.J., Melville, D.M. & Leicester, R.J. Review article: chemoprevention of colorectal cancer, 1
- COX-2 inhibitors, 197, 1051
- COX-2 selective inhibitors, 817
- Crema, F. *see* Tonini, M.
- Cremonini, F. *see* Santarelli, L.
- Criegee-Rieck, M. *see* Dormann, H.
- Crohn's disease, 287, 295, 427, 511, 671, 953, 1019, 1073, 1147, 1269
- Cui, H. *see* Bautista, J.
- Culture-guided, 789
- Cyclosporin A, 209
- CYP2C19, 113
- Cytokine(s), 671, 1063
- D2 receptor blockade, 379
- Dagalp, K. *see* Uygun, A.
- Dahlerup, J.F. *see* Vilien, M.
- Dall'Ozzo, S. *see* Louis, E.
- D'Ambra, G. *see* Panzuto, F.
- Dammann, H.-G., Saleki, M., Torz, M., Schulz, H.-U., Krupp, S., Schürer, M., Timm, J. & Gessner, U. Effects of buffered and plain acetylsalicylic acid formulations with and without ascorbic acid on gastric mucosa in healthy subjects 367
- Daniels, B. *see* Abraham, N.S.
- Das, S. *see* Aithal, G.P.
- Davis, D.M. *see* Ward, E.M.
- Davis, K.J. *see* Higgins, P.D.R.

- De Francesco, V., Della Valle, N., Stoppino, V., Amoroso, A., Muscatiello, N., Panella, C. & Ierardi, E. Effectiveness and pharmaceutical cost of sequential treatment for *Helicobacter pylori* in patients with non-ulcer dyspepsia, 993
- De Francesco, V., Zullo, A., Margiotta, M., Marangi, S., Burattini, O., Berloco, P., Russo, F., Barone, M., Di Leo, A., Minenna, M.F., Stoppino, V., Morini, S., Panella, C., Francavilla, A. & Ierardi, E. Sequential treatment for *Helicobacter pylori* does not share the risk factors of triple therapy failure, 407
- De Kam, M.L. *see* Kamerling, I.M.C.
- De Ponti, F. *see* Tonini, M.
- De Sanctis, G. *see* Angelico, M.
- De Silva, A. *see* Langmead, L.
- De Vos, M. *see* Louis, E.
- De Wit, N.J. *see* Bijkerk, C.J.
- Decision analysis, 1247
- Deibert, P. *see* Herrlinger, K.R.
- Delayed diagnosis, 981
- Delgado-Aros, S. *see* Cremonini, F.
- Della Valle, N. *see* De Francesco, V.
- Della Vecchia, R. *see* Angelico, M.
- Delle Fave, G. *see* Panzuto, F.
- Demarchi, B., Vos R., Deprez P., Janssens J., Tack J. Influence of a lipase inhibitor on gastric sensitivity and accommodation to an orally ingested meal, 1261
- Demelia, L. *see* Angelico, M.
- Deprez, P. *see* Demarchi, B.
- Devault, K.R. *see* Ward, E.M.
- Deveci, S. *see* Uygun, A.
- Developing country, 1315
- D'Haens, G. *see* Marchal, L.
- Dhar, A. *see* Kang, J.Y.
- D'Hoore, A. *see* Marchal, L.
- Di Candilo, F. *see* Angelico, M.
- Di Caro, S., Delgado-Aros, S., Sepulveda, A., Gasbarrini, G., Gasbarrini, A. & Camilleri, M. Notice of retraction of article. Meta-analysis: the relationship between *Helicobacter pylori* infection and gastro-oesophageal reflux disease, 145
- Di Caro, S. *see* Cremonini, F.
- Di Giulio, E. *see* Panzuto, F.
- Di Leo, A. *see* De Francesco, V.
- Di Sabatino, A., Ciccocioppo, R., Benazzato, L., Sturniolo, G.C. & Corazza, G.R. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients, 1019
- Diagnosis, 157, 829, 923
- Diago, M. *see* Apolinario, A.
- Diaz-Rubio, M., Moreno-Elola-Olaso, C., Rey, E., Locke III, G.R. & Rodriguez-Artalejo, F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population, 95
- Dietary fiber, 245
- Dietary supplements, 245
- Dignass, A. *see* Büning, C.
- Disease management, 63
- Dixon, A. *see* Todd, J.A.
- Dominguez-Muñoz, E. *see* Gisbert, J.P.
- Donnelly, J.R. *see* Gremse, D.A.
- Dormann, H., Criegee-Rieck, M., Neubert, A., Egger, T., Levy, M., Hahn, E.G. & Brune, K. Implementation of a computer-assisted monitoring system for the detection of adverse drug reactions in gastroenterology, 303
- Double-blinded randomized controlled study, 455
- Doxycycline, 789
- Drug effects, 679
- Drug safety, 179, 679
- Drug-induced, 391
- Drug-resistant mutants, 323
- Dubois, R.W. *see* Graham, D.Y.
- Dubois, R.W., Melmed, G.Y., Henning, J.M. & Laine, L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy, 197
- Ducrotte, P. *see* Galmiche, J.P.
- Dulbecco, P. *see* Zentilin, P.
- Dupont, A.W. *see* Raines, D.L.
- Dwarakanath, D. *see* Rubin, G.P.
- Dyard, F. *see* Bouhnik, Y.
- Dyspepsia, 233, 917, 1099
- Dysplasia, 879
- Early response, 339
- Economic evaluation, 349
- Egger, T. *see* Dormann, H.
- El Ghoul, Z. *see* Louis, E.
- El-Serag, H.B., Aguirre, T., Kuebler, M. & Sampliner, R.E. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy, 1255
- El-Serag, H.B., Pilgrim, P. & Schoenfeld, P. Systematic review: natural history of irritable bowel syndrome, 861
- El-Serag, H.B. & Talley, N.J. Systematic review: the prevalence and clinical course of functional dyspepsia, 643
- Emerenziani, S. *see* Biancone, L.
- Emmanuel, A.V., Shand, A.G. & Kamm, M.A. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response, 687
- Empirical trial, 1123
- Endoscopic retrograde cholangiopancreatography, 1153
- Endoscopy, 989
- Enteral stent, 901
- Epidemiological studies, 497
- Epidemiology, 233, 287, 1025, 1217
- Eradication, 219
- Eradication predictors, 407
- Eradication therapy, 1181
- Erdmann, J., Lippl, F., Klose, G. & Schusdziarra, V. Cholesterol lowering effect of dietary weight loss and orlistat treatment – efficacy and limitations, 1173
- Ernst, E. *see* Borrelli, F.
- Erythromycin, 687
- Escobedo, S. *see* Chiba, N.

- Eslick, G.D., Howell, S.C., Hammer, J. & Talley, N.J. Empirically derived symptom sub-groups correspond poorly with diagnostic criteria for functional dyspepsia and irritable bowel syndrome. A factor and cluster analysis of a patient sample, 133
- Esomeprazole, 655, 1105
- Etest, 1315
- Ethnic differences, 765
- Evidence based medicine, 1235
- Extrapyramidal reactions, 379
- Factor analysis, 133
- Faecal, 923
- Faecal continence, 311
- Faecal incontinence, 829
- Faeces, 923
- Failure of medical therapy, 1079
- Fakheri, H., Merat, S., Hosseini, V. & Malekzadeh, R. Low-dose furazolidone in triple and quadruple regimens for *Helicobacter pylori* eradication, 89
- Fallingborg, J. see Vilien, M.
- Fallone, C.A. see Barkun, A.N.
- Fan, S.-T. see Hui, C.-K.
- Fan, S.T. see Lam, C.-M.
- Fan, S.-T. see Poon, R.T.-P.
- Färkkilä, M.A. see Koivisto, T.T.
- Fass, R. see Bautista, J.
- Fatty liver, 537
- Feakins, R.M. see Langmead, L.
- Fellermann, K. see Herrlinger, K.R.
- Fennell, J.M. see Ho, G.T.
- Ferenci, P. Review article: diagnosis and current therapy of Wilson's disease, 157
- Ferrante, M. see Marchal, L.
- Fett, S.L. see Halder, S.L.S.
- Fickert, P. see Wenzl, H.H.
- Fina, D. see Biancone, L.
- Fine, D.R. see Trebble, T.M.
- Fini, L. see Candelli, M.
- Fiocca, R. see Zentilin, P.
- Fiorentini, P. see Galmiche, J.P.
- Firpi, R.J., Tran, T.T., Flores, P., Nissen, N., Colquhoun, S., Shackleton, C., Martin, P., Vierling, J.M. & Poordad, F.F. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent, 1033
- Fischer, C. see Herrlinger, K.R.
- Fissure-in-ano, 695
- Fistula, 295
- Fleig, W.E. see Herrlinger, K.R.
- Flores, P. see Firpi, R.J.
- Flourié, B. see Bouhnik, Y.
- Fong, C.Y. see Chan, A.O.O.
- Forbes, A. see Bloom, S.
- Fox, M., Thumshirn, M., Menne, D., Stutz, B., Fried, M. & Schwizer, W. The pathophysiology of faecal spotting in obese subjects during treatment with orlistat, 311
- Fragmentation, 545
- Francavilla, A. see De Francesco, V.
- Francioso, S. see Angelico, M.
- Freeman, J.G. see Austin, A.S.
- Freston, J.W., Pilmer, B.L., Chiu, Y.-L., Wang, Q., Stolle, J.C., Griffin, J.S. & Lee, C.Q. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole, 1111
- Fried, M. see Fox, M.
- Friis, S. see Nørgård, B.
- Fullerton, H. see Bautista, J.
- Functional colonic diseases, 245
- Functional dyspepsia, 219, 631, 643, 797
- Functional gastrointestinal disorders, 133, 1235
- Furazolidone, 89
- Gabrielli, M. see Santarelli, L.
- Gallbladder, 797
- Gallbladder motility, 601
- Gallstone formation, 601
- Galmiche, J.-P. see Zerbib, F.
- Galmiche, J.P., Bruley Des Varannes, S., Ducrotté, P., Sacher-Huvelin, S., Vavasseur, F., Tacoen, A., Fiorentini, P. & Homerin, M. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers, 655
- Gambaro, C. see Zentilin, P.
- García-Monzón, C. see Apolinario, A.
- Gasbarrini, A. see Cammarota, G.
- Gasbarrini, A. see Candelli, M.
- Gasbarrini, A. see Cremonini, F.
- Gasbarrini, A. see Santarelli, L.
- Gasbarrini, G. see Cammarota, G.
- Gasbarrini, G. see Candelli, M.
- Gasbarrini, G. see Cremonini, F.
- Gasbarrini, G. see Santarelli, L.
- Gastric accommodation, 415, 1261
- Gastric acid, 1105
- Gastric acid secretion, 253, 1181
- Gastric adenocarcinoma, 841
- Gastric barostat, 1261
- Gastric carcinoma, 989
- Gastric mucosal atrophy, 1181
- Gastric outflow obstruction, 901
- Gastric pH, 655
- Gastric sensitivity, 415, 1261
- Gastric tachyarrhythmia, 583
- Gastric tone, 415
- Gastric ulcer, 989
- Gastroesophageal reflux disease, 463
- Gastrointestinal bleeding, 591
- Gastrointestinal cancer, 497
- Gastrointestinal oncology, 1, 191, 401, 771, 901, 981, 1159
- Gastrointestinal physiology, 39
- Gastrointestinal prokinesia, 379
- Gastro-oesophageal reflux, 95, 931
- Gene, E. see Gisbert, J.P.
- General Practice, 917
- Genschel, J. see Büning, C.



- Gentile, S. *see* Angelico, M.  
 GERD, 455, 463, 1041  
 Geremia, A. *see* Biancone, L.  
 Gessner, U. *see* Dammann, H.-G.  
 Giacobbe, A. *see* Mangia, A.  
 Giannini, E.G. & Testa, R. Letter to the Editors, 827  
 Gibson, J.A. *see* Green, J.R.B.  
 Gimona, A. *see* Kivitz, A.J.  
 Gisbert, J.P., Khorrami, S., Carballo, F., Calvet, X., Gene, E. & Dominguez-Muñoz, E. Meta-analysis: *Helicobacter pylori* eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer, 617  
 Gisbert, J.P., Trapero, M., Calvet, X., Mendoza, J., Quesada, M., Güell, M. & Pajares, J.M. Evaluation of three different tests for the detection of stool antigens to diagnose *Helicobacter pylori* infection in patients with upper gastrointestinal bleeding, 923  
 Glucocorticoid Receptor, 47  
 Gluten-free, 1277  
 Goddard, C.J.R. *see* Ho, G.T.  
 Goland, S. *see* Kaptan, K.  
 Goldthorpe, S. *see* Langmead, L.  
 Gorard, D.A. *see* Kitiyakara, T.  
 GORD, 253  
 Grace, E. *see* Chiba, N.  
 Graham, D.Y. *see* Chan, F.K.L.  
 Graham, D.Y., Laine, L. & Dubois, R.W. Letter to the Editors, 1323  
 Granström, M. *see* Wheeldon, T.-U.  
 Green tea, 497  
 Green, J.R.B., Swan, C.H.J., Gibson, J.A., Kerr, G.D., Swarbrick, E.T. & Thornton, P.C. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study, 435  
 Greinwald, R. *see* Herrlinger, K.R.  
 Gremse, D.A., Donnelly, J.R., Kukulka, M.J., Lloyd, E. & Lee, C. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe, 1211  
 Grieco, A. *see* Angelico, M.  
 Grieco, A. *see* Cammarota, G.  
 Griffin, J.S. *see* Freston, J.W.  
 Grol, R. *see* Krol, N.  
 Gronbæk, K. *see* Vilien, M.  
 Growth factors, 1019  
 Growth/Development/Nutrition, 245, 583, 1277  
 Güell, M. *see* Gisbert, J.P.  
 Guidelines, 197  
 Guillemot, F. *see* Bouhnik, Y.  
 Gulsen, M. *see* Uygün, A.  
 Guslandi, M. *see* Brisinda, G.  
*H. pylori*, 253, 349, 993, 1181, 1309  
 Haaijer-Ruskamp, F. *see* Krol, N.  
 Hadziyannis, S.J. *see* Papatheodoridis, G.V.  
 Hahn, E.G. *see* Dormann, H.  
 Halder, S.L.S., Locke III, G.R., Talley, N.J., Fett, S.L., Zinsmeister, A.R. & Melton III, L.J. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study, 233  
 Halphen, M. *see* Brisinda, G.  
 Hammer, J. *see* Eslick, G.D.  
 Hammer, J. & Schmidt, B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough, 1105  
 Hanauer, S.B. *see* Sandborn, W.J.  
 Harb, G. *see* Jensen, D.M.  
 Haruma, K. *see* Kai, H.  
 Haugk, B. *see* Aithal, G.P.  
 Hauschildt Juhl, H. *see* Meineche-Schmidt, V.  
 Hawkey, C. *see* Kivitz, A.J.  
 HBsAg, 771  
 HCC, 771  
 HCV chronic hepatitis, 331  
 Healing, 359  
 Health economics, 1247  
 Health service research, 191, 1247  
 Heartburn, 95, 463  
 Heikkinen, M. *see* Koivisto, T.T.  
*Helicobacter*, 841  
*Helicobacter pylori*, 89, 107, 219, 407, 789, 923, 1009, 1315  
 Henning, J.M. *see* Dubois, R.W.  
 Heparin, 871  
 Hepatitis, 323  
 Hepatitis C, 1159  
 Hepatitis C virus, 551  
 Hepatitis vaccination, 715  
 Hepatocellular carcinoma, 999, 1301  
 Hepatotoxicity, 391  
 Herba, K. *see* Barkun, A.N.  
 Herbal, 271  
 Herbal therapy, 739  
 Herdman, C.R. *see* Schwartz, D.A.  
 Herrlinger, K.R., Fellermann, K., Fischer, C., Kreisel, W., Deibert, P., Schoelmerich, J., Fleig, W.E., Ruhl, A., Reinshagen, M., Greinwald, R., Stange, E.F. & Schwab, M. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease, 1269  
 Hertvig, E. *see* Sturegård, E.  
 Hiatal hernia, 663  
 Hiele, M. *see* Marchal, L.  
 Higgins, P.D.R., Davis, K.J. & Laine, L. Systematic review: the epidemiology of ischaemic colitis, 729  
 High dose lansoprazole, 1123  
 Hinterleitner, T.A. *see* Wenzl, H.H.  
 Ho, G.T., Mowat, C., Goddard, C.J.R., Fennell, J.M., Shah, N.B., Prescott, R.J. & Satsangi, J. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery, 1079  
 Ho, P. *see* Lam, C.-M.  
 Hoang, T.T.H. *see* Wheeldon, T.-U.

- Hoes, A.W. *see* Bijkerk, C.J.  
Holt, H. *see* Langmead, L.  
Holtmann, G. *see* Madisch, A.  
Homerin, M. *see* Galmiche, J.P.  
Horikawa, Y. *see* Shimatani, T.  
Hormone replacement therapy, 563  
Hormones and Receptors, 47, 687, 695, 797, 805  
Hospital stay, 63  
Hosseini, V. *see* Fakheri, H.  
Host factors, 219  
Hotz, J. *see* Madisch, A.  
Houghton, L.A. *see* Calvert, E.L.  
Howell, S.C. *see* Eslick, G.D.  
Hu, P.J. *see* Xiong, L.S.  
Hu, W.H.C. *see* Hui, C.-K.  
Hu, W.H.C. *see* Wong, W.M.  
Huang, J.Q. *see* Wong, W.M.  
Huang, Y.-H. *see* Huo, T.  
Huang, Y.-H. *see* Huo, T.-I.  
Hui, C.-K., Liu, C.-L., Lai, K.-C., Chan, S.-C., Hu, W.H.C., Wong, W.-M., Cheung, W.W., Ng, M., Yuen, M.-F., Chan, A.O., Lo, C.M., Fan, S.-T. & Wong, B.C.Y. Outcome of emergency ERCP for acute cholangitis in patients 90 years of age and older, 1153  
Hui, W.M. *see* Wong, W.M.  
Human, 889  
Hungin, A.P.S. *see* Panter, S.J.  
Hungin, A.P.S. *see* Rubin, G.P.  
Hunter, M.M. & McKay, D.M. Review article: helminths as therapeutic agents for inflammatory bowel disease, 167  
Huo, T., Huang, Y.-H., Wu, J.-C., Chiang, J.-H., Lee, P.-C., Chang, F.-Y. & Lee, S.-D. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey, 1301  
Huo, T.-I., Wu, J.-C., Huang, Y.-H., Chiang, J.-H., Lee, P.-C., Chang, F.-Y. & Lee, S.-D. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome, 999  
Hvenegaard, A. *see* Meineche-Schmidt, V.  
HVPG measurement, 571  
Hyperhomocysteinemia, 107  
Hyperlipidemia, 1173  
Hyperprolactinaemia, 379  
Iacobellis, A. *see* Mangia, A.  
IBD, 941  
IBS visceral hypersensitivity, 123, 271  
ICAM-1, 281  
Ierardi, E. *see* De Francesco, V.  
Iijima, K., Sekine, H., Koike, T., Imatani, A., Ohara, S. & Shimosegawa, T. Long-term effect of *Helicobacter pylori* eradication on the reversibility of acid secretion in profound hypochlorhydria, 1181  
Iiritano, E. *see* Zentilin, P.  
Ileal involvement, 1073  
Ileal mucosa, 671  
Ileocecal resection, 1073  
Imatani, A. *see* Iijima, K.  
Immune deviation, 167  
Immunology and Microbiology, 47, 89, 167, 511, 521, 551, 749, 1009, 1033, 1293  
Immunosuppression, 427  
Incontinence, 481  
Inflammatory bowel disease, 63, 755  
Inflammatory disorders, 47, 179, 427, 511, 521, 529, 551, 729, 739, 749, 755, 871, 1019, 1063, 1189, 1269  
Infliximab, 295  
Infliximab therapy, 1019  
iNOS IL-6 gastrin, 1309  
Inoue, M. *see* Shimatani, T.  
Insulin resistance, 537  
Integrated intragastric acidity, 443  
Interferon, 339  
Interferon- $\alpha$ , 25  
Interleukin 6, 671  
Intestinal disorders, 1, 47, 123, 179, 197, 233, 245, 263, 295, 311, 511, 671, 687, 695, 729, 739, 749, 755, 861, 901, 1009, 1025, 1063, 1079, 1235, 1277  
Intestinal fibrosis, 1019  
Intestinal microflora, 889  
Intragastric pH, 443  
Intragastric pH > 4, 113  
Intravenous, 1111  
Iran, 89  
Iron deficiency anaemia, 663  
Irritable bowel syndrome, 133, 263, 271, 1199, 1217  
Irvine, E.J. *see* Bloom, S.  
Isik, A.T. *see* Uygun, A.  
Ito, M. *see* Kai, H.  
Jacobsen, J. *see* Nørgård, B.  
Jain, R. *see* Malik, A.H.  
Jansen, J.B.M.J. *see* van Rossum, L.G.M.  
Janssens, J. *see* Demarchi, B.  
Jensen, D.M., Cotler, S.J., Lam, H., Harb, G. & Shillington, A. A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres, 69  
Jess, T., Winther, K.V., Munkholm, P., Langholz, E. & Binder, V. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark, 287  
Jewell, D.P. *see* Langmead, L.  
Johns, C.E. *see* Newton, J.L.  
Johnsen, S.P. *see* Nørgård, B.  
Jonderko, K. *see* Mangel, A.W.  
Kadayifci, A. *see* Uygun, A.  
Kai, H., Ito, M., Kitadai, Y., Tanaka, S., Haruma, K. & Chayama, K. Chronic gastritis with expression of inducible nitric oxide

- synthase is associated with high expression of interleukin-6 and hypergastrinaemia, 1309
- Kamerling, I.M.C., Van Haarst, A.D., De Kam, M.L., Cohen, A.F., Masclee, A.A.M. & Burggraaf, J. Gallbladder volume as a biomarker for the motilin effect in healthy volunteers and patients with functional dyspepsia, 797
- Kamm, M.A. *see* Emmanuel, A.V.
- Kane, S.V. *see* Loftus Jr, E.V.
- Kang, J.Y., Dhar, A., Pollok, R., Leicester, R.J., Benson, M.J., Kumar, D., Melville, D., Neild, P.J., Tibbs, C.J. & Maxwell, J.D. Diverticular disease of the colon: ethnic differences in frequency, 765
- Kaptan, K., Beyan, C., Malnick, S., Goland, S., Rajendra, S. & Alahuddin, S. Letters to the Editors, 703
- Kasicka-Jonderko, A. *see* Mangel, A.W.
- Katz, P.O. *see* Tutuian, R.
- Kaukinen, K. *see* Collin, P.
- Keeffe, E.B. *see* Lin, O.S.
- Keeffe, E.B. *see* Reiss, G.
- Kennedy, W. *see* Barkun, A.N.
- Kerr, G.D. *see* Green, J.R.B.
- Khorrami, S. *see* Gisbert, J.P.
- Küllerich, S. *see* Bloom, S.
- Kitadai, Y. *see* Kai, H.
- Kitagawa, T. *see* Yamamoto, T.
- Kitiyakara, T., Bailey, D.M., McIntyre, A.S. & Gorard, D.A. Adenomatous colonic polyps are rare in ulcerative colitis, 879
- Kivitz, A.J., Naytger, S., Schimansky, T., Gimona, A., Thurston, H.J. & Hawkey, C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis, 1189
- Kling, K. *see* Büning, C.
- Klose, G. *see* Erdmann, J.
- Klotz, U. *see* Treiber, G.
- K-means, 133
- Knottnerus, J.A. *see* Bijkerk, C.J.
- Koike, T. *see* Iijima, K.
- Koivisto, T.T., Rautelin, H.I., Voutilainen, M.E., Niemelä, S.E., Heikkinen, M., Sipponen, P.I. & Färkkilä, M.A. Primary *Helicobacter pylori* resistance to metronidazole and clarithromycin in the Finnish population, 1009
- k-ras, 1225
- kreisel, W. *see* Herrlinger, K.R.
- Krol, N., Wensing, M., Haaijer-Ruskamp, F., Muris, J.W.M., Numans, M.E., Schattenberg, G., Van Balen, J. & Grol, R. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial, 917
- Krüger, S. *see* Büning, C.
- Krupp, S. *see* Dammann, H.-G.
- Kuebler, M. *see* El-Serag, H.B.
- Kukulka, M.J. *see* Gremse, D.A.
- Kumar, D. *see* Kang, J.Y.
- Kumar, K.S. *see* Malik, A.H.
- Kuroiwa, T. *see* Shimatani, T.
- Laboratory signals, 303
- Ladabaum, U. *see* Mein, S.M.
- Laheij, R.J.F. *see* van Rossum, L.G.M.
- Lai, C.L. *see* Chan, A.O.O.
- Lai, K.-C. *see* Hui, C.-K.
- Lai, K.C. *see* Wong, W.M.
- Laine, L. *see* Dubois, R.W.
- Laine, L. *see* Graham, D.Y.
- Laine, L. *see* Higgins, P.D.R.
- Lam, C.L.K. *see* Wong, W.M.
- Lam, C.M. *see* Chan, A.O.O.
- Lam, C.-M., Chan, A.O.O., Ho, P., Ng, I.O.-L., Lo, C.M., Liu, C.L., Poon, R.T.P. & Fan, S.T. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients — implications for screening, 771
- Lam, H. *see* Jensen, D.M.
- Lam, K.F. *see* Wong, W.M.
- Lam, S.K. *see* Wong, W.M.
- Lamivudine, 25, 323
- Langholz, E. *see* Bloom, S.
- Langholz, E. *see* Jess, T.
- Langmead, L., Feakins, R.M., Goldthorpe, S., Holt, H., Tsironi, E., De Silva, A., Jewell, D.P. & Rampton, D.S. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis, 739
- Langmead, L., Makins, R.J. & Rampton, D.S. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa *in vitro*, 521
- Lansoprazole, 455, 1111, 1211
- Lassen, M.R. *see* Bloom, S.
- Lawson, M.J. *see* Tagore, K.S.
- Leandro, G. *see* Mangia, A.
- Lee, C. *see* Gremse, D.A.
- Lee, C.Q. *see* Freston, J.W.
- Lee, J. *see* Chiba, N.
- Lee, K.-J., Vos, R. & Tack, J. Effects of capsaicin on the sensorimotor function of the proximal stomach in humans, 415
- Lee, P.-C. *see* Huo, T.
- Lee, P.-C. *see* Huo, T.-I.
- Lee, S.-D. *see* Huo, T.
- Lee, S.-D. *see* Huo, T.-I.
- Leicester, R.J. *see* Courtney, E.D.J.
- Leicester, R.J. *see* Kang, J.Y.
- Leiper, K. *see* Bloom, S.
- Lembo, T. *see* Schwetz, I.
- Leo, P. *see* Soncini, M.
- Leslie, W.D. *see* Bernstein, C.N.
- Leung, N.W.-Y. *see* Wong, V.W.-S.
- Levin, T.R. *see* Tagore, K.S.
- Levine, M.E., Muth, E.R., Williamson, M.J. & Stern, R.M. Protein-predominant meals inhibit the development of gastric tachyarrhythmia, nausea and the symptoms of motion sickness, 583
- Levy, M. *see* Dormann, H.
- Libby, G.W. *see* Castle, M.Z.D.
- Lin, O.S., Keeffe, E.B., Sanders, G.D. & Owens, D.K. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C, 1159



- Lindsay, J.O., Andreyev, H.J.N., Vlavianos, P. & Westaby, D. Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass, 901
- Linear height*, 253
- Lipase*, 601
- Lipase inhibitor*, 1261
- Lipidol*, 779
- Lippl, F. *see* Erdmann, J.
- Liu, C.-L. *see* Hui, C.-K.
- Liu, C.L. *see* Lam, C.-M.
- Liver biopsy*, 545
- Liver cirrhosis*, 999, 1301
- Liver descriptors*, 25, 79, 209, 401, 545, 551, 999, 1033, 1159, 1301
- Liver transplantation*, 157
- Lloyd, E. *see* Gremse, D.A.
- Lo Iacono, O. *see* Apolinario, A.
- Lo, C.M. *see* Hui, C.-K.
- Lo, C.M. *see* Lam, C.-M.
- Lochs, H. *see* Büning, C.
- Locke III, G.R. *see* Diaz-Rubio, M.
- Locke III, G.R. *see* Halder, S.L.S.
- Locke III, G.R., Yawn, B.P., Wollan, P.C., Melton III, L.J., Lydick, E. & Talley, N.J. Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population, 1025
- LODT*, 1211
- Loftus Jr, E.V., Kane, S.V. & Bjorkman, D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis, 179
- Lorente, R. *see* Apolinario, A.
- Louis, E., El Ghoul, Z., Vermeire, S., Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J.-F. & Watier, H. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease, 511
- Lowson, D. *see* Bloom, S.
- Lucey, M.R. *see* Tome, S.
- Luckow, A. *see* Meineche-Schmidt, V.
- Lumiracoxib*, 1189
- Lydick, E. *see* Locke III, G.R.
- Mabisombi, A. *see* Brisinda, G.
- Madisch, A., Holtmann, G., Plein, K. & Hotz, J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial, 271
- Maggiore, G. *see* Sciveres, M.
- Magni (on behalf of the Ring Study Group), G. *see* Soncini, M.
- Mahida, Y.R. *see* Austin, A.S.
- Maintenance treatment*, 1147
- Majano, P.L. *see* Apolinario, A.
- Mäki, M. *see* Collin, P.
- Makins, R.J. *see* Langmead, L.
- Malekzadeh, R. *see* Fakheri, H.
- Malet, P.F. *see* Malik, A.H.
- Malfertheiner, P. *see* Treiber, G.
- Malik, A.H., Kumar, K.S., Malet, P.F., Jain, R., Prasad, P. & Ostapowicz, G. Correlation of percutaneous liver biopsy fragmentation with the degree of fibrosis, 545
- Malnick, S. *see* Kaptan, K.
- Mangel, A.W., Jonderko, K., Kasicka-Jonderko, A. & Blonska-Fajfrowska, B. Letters to the Editors, 141
- Mangia, A., Spinzi, G., Vuturo, O., Pazienza, V., Iacobellis, A., Piattelli, M., Giacobbe, A., Leandro, G., Piermanni, V., Minoli, G., Montalto, G. & Andriulli, A. Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study, 331
- Manning criteria*, 1217
- Mansi, C. *see* Zentilin, P.
- Marangi, S. *see* De Francesco, V.
- Marchal, L., D'Haens, G., Van Assche, G., Vermeire, S., Noman, M., Ferrante, M., Hiele, M., Bueno De Mesquita, M., D'Hoore, A., Penninckx, F. & Rutgeerts, P. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study, 749
- Margiotta, M. *see* De Francesco, V.
- Maria, G. *see* Brisinda, G.
- Marniga, G. *see* Brisinda, G.
- Martin, P. *see* Firpi, R.J.
- Martino, A. *see* Cammarota, G.
- Masclee, A.A.M. *see* Kamerling, I.M.C.
- Mastracci, L. *see* Zentilin, P.
- Mathus-Vliegen, E.M.H., Van Ierland-Van Leeuwen, M.L. & Terpstra, A. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity, 601
- Matin, K. *see* Schwetz, I.
- Matsumoto, K. *see* Yamamoto, T.
- Maxwell, J.D. *see* Kang, J.Y.
- May, F.E.B. *see* Newton, J.L.
- Mayer, E.A. *see* Schwetz, I.
- McCormick, P.A. *see* O'Keefe, C.
- McIntyre, A.S. *see* Kitiyakara, T.
- McKay, D.M. *see* Hunter, M.M.
- McLaughlin, J.K. *see* Nørgård, B.
- Median intragastric pH value*, 113
- Medical Decision Analysis*, 191
- Medical therapy*, 295, 511
- Medical treatment*, 953
- Medication toxicity*, 1033
- Mein, S.M. & Ladabaum, U. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis, 1199
- Meineche-Schmidt, V., Hauschildt Juhl, H., Østergaard, J.E., Luckow, A. & Hvenegaard, A. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care, 907
- Melmed, G.Y. *see* Dubois, R.W.
- Melton III, L.J. *see* Halder, S.L.S.
- Melton III, L.J. *see* Locke III, G.R.
- Melville, D. *see* Kang, J.Y.
- Melville, D.M. *see* Courtney, E.D.J.
- Mendoza, J. *see* Gisbert, J.P.

- Menne, D. *see* Fox, M.  
 Merat, S. *see* Fakheri, H.  
*Meta-Analysis*, 631  
*Metformin*, 537  
*Methodology*, 631  
*Methotrexate*, 295  
*Methylated 6-thioguanine nucleotides*, 1269  
*Metronidazole*, 1009  
*MIC*, 1315  
 Michel, C. *see* Bouhnik, Y.  
*Microsatellite instability marker*, 1225  
 Middel, P. *see* Raddatz, D.  
 Miele, L. *see* Cammarota, G.  
 Minenna, M.F. *see* De Francesco, V.  
 Miner Jr, P., Wedel, M., Bane, B. & Bradley, J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis, 281  
 Minić, M. *see* Brisinda, G.  
 Minoli, G. *see* Mangia, A.  
*Misoprostol*, 1051  
 Moayyedi, P. *see* Abraham, N.S.  
 Molnar, B. *see* Ruzsovics, A.  
*Monitoring*, 449  
 Moniz, C. *see* Pereira, S.P.  
 Moniz, C. *see* Trebble, T.M.  
 Mönnikes, H. *see* Stanghellini, V.  
 Montalto, G. *see* Mangia, A.  
*Morbidity*, 779  
 Moreno-Elola-Olaso, C. *see* Diaz-Rubio, M.  
 Morini, S. *see* De Francesco, V.  
*Motilin*, 797  
*Motility and nerve-gut interactions*, 95, 123, 271, 311, 415, 583, 601, 687, 695, 805, 861, 1025, 1235, 1261  
 Mowat, C. *see* Ho, G.T.  
 Mullee, M.A. *see* Trebble, T.M.  
*Multicenter study*, 63  
 Munakata, J. *see* Schwetz, I.  
 Munck, L.K. *see* Vilien, M.  
 Munkholm, P. *see* Jess, T.  
 Muris, J.W.M. *see* Bijkerk, C.J.  
 Muris, J.W.M. *see* Krol, N.  
 Muscatiello, N. *see* De Francesco, V.  
*Mutation analysis*, 157  
 Muth, E.R. *see* Levine, M.E.  
*Mycophenolate mofetil*, 427  
 Naliboff, B. *see* Schwetz, I.  
*Nausea*, 583  
 Nayiager, S. *see* Kivitz, A.J.  
*NCCP*, 1123  
 Nedrow, S.I. *see* Ward, E.M.  
 Neild, P.J. *see* Kang, J.Y.  
 Neubert, A. *see* Dormann, H.  
*Neurotensin*, 931  
 Neut, C. *see* Bouhnik, Y.  
 Newton, J.L., Johns, C.E. & May, F.E.B. Review article: the ageing bowel and intolerance to aspirin, 39  
 Ng, F.-H., Wong, B.C.-Y., Wong, S.-Y., Chen, W.-H. & Chang, C.-M. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk — a single-blind, randomized controlled study, 359  
 Ng, I.O.-L. *see* Lam, C.-M.  
 Ng, M. *see* Hui, C.-K.  
 Niemelä, S.E. *see* Koivisto, T.T.  
 Nilsson, L.E. *see* Wheeldon, T.-U.  
 Nissen, N. *see* Firpi, R.J.  
 Nista, E.C. *see* Cammarota, G.  
 Nista, E.C. *see* Candelli, M.  
 Nista, E.C. *see* Santarelli, L.  
*Nocturnal acid breakthrough*, 655, 1105  
*Nocturnal gastric acid breakthrough (NAB)*, 113  
*NOD2*, 1073  
 Nolan, N. *see* O'Keefe, C.  
 Noman, M. *see* Marchal, L.  
*Nonalcoholic steatohepatitis*, 537  
*Non-cardiac chest pain*, 1123  
*Non-ulcer dyspepsia*, 133, 993  
 Nørgård, B., Pedersen, L., Jacobsen, J., Rasmussen, S.N. & Sørensen, H.T. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception, 679  
 Nørgård, B., Pedersen, L., Johnsen, S.P., Tarone, R.E., McLaughlin, J.K., Friis, S. & Sørensen, H.T. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study, 817  
 Nørregaard, P. *see* Vilien, M.  
*NSAIDs*, 197, 817, 1051  
 Numans, M.E. *see* Krol, N.  
*Nutrition*, 779, 1173  
 O'Keefe, C., Baird, A.W., Nolan, N. & McCormick, P.A. Cholestatic pruritus — the role of cutaneous mast cells and nerves, 1293  
 O'Morain, C. *see* Bloom, S.  
*Obesity*, 311, 601, 1173  
 Ockenga, J. *see* Büning, C.  
 O'Donohue, J. *see* Pereira, S.P.  
*Oesophagus*, 449  
*Oesophageal disorders*, 907  
*Oesophageal manometry*, 931  
*Oesophageal varices*, 571  
*Oesophageal / gastric / duodenal disorders*, 89, 95, 191, 197, 233, 463, 591, 601, 841, 1009, 1111, 1181, 1189, 1277  
 O'Flanagan, H. *see* Panter, S.J.  
 Ohara, S. *see* Iijima, K.  
 Ohning, G. *see* Schwetz, I.  
*On demand treatment*, 907  
*Oral syringe*, 1211  
*Orally disintegrating tablet*, 1211  
*Orlistat*, 311, 601, 1173  
 Orm, S. *see* Bloom, S.

- Ostapowicz, G. *see* Malik, A.H.  
Osteoporosis, 941  
Østergaard, J.E. *see* Meineche-Schmidt, V.  
Outcome, 981, 1079, 1153  
Owens, D.K. *see* Lin, O.S.  
Ozgurtas, T. *see* Uygun, A.
- p53, 1225  
Paintaud, G. *see* Louis, E.  
Pajares, J.M. *see* Gisbert, J.P.  
Palla, G. *see* Sciveres, M.  
Pallone, F. *see* Biancone, L.  
Pancreatic disorders, 901  
Panella, C. *see* De Francesco, V.  
Panter, S.J., O'Flanagan, H., Bramble, M.G. & Hungin, A.P.S.  
Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome, 981  
Panzuto, F., Di Giulio, E., Capurso, G., Baccini, F., D'Ambra, G., Delle Fave, G. & Annibale, B. Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment, 663  
Papatheodoridis, G.V. & Hadziyannis, S.J. Review article: current management of chronic hepatitis B, 25  
Parruti, G. *see* Angelico, M.  
Paternal drug exposure, 679  
Patient sample, 133  
Patient-directed strategy, 917  
Patients with persistently normal ALT, 331  
Pazienza, V. *see* Mangia, A.  
Pedersen, L. *see* Nørgård, B.  
Peginterferon, 551  
Pelvic floor, 481  
Penninckx, F. *see* Marchal, L.  
Pentoxifylline, 79  
Peptic ulcer, 359  
Peptic ulcer disease, 993  
Percutaneous injection, 1301  
Pereira, S.P., O'Donohue, J., Moniz, C., Phillips, M.G., Abrahá, H., Buxton-Thomas, M. & Williams, R. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial, 563  
Pérez, C. *see* Apolinario, A.  
Perianal disease, 427  
Perianal fistula, 953  
Perri, F. *see* Rajendra, S.  
Petritsch, W. *see* Wenzl, H.H.  
Petruzziello, C. *see* Biancone, L.  
pH, 449  
pH monitoring, 1105  
Pharmaceutical cost, 993  
Pharmacodynamics, 1111  
Pharmacogenetics, 511  
Pharmacokinetics, 1111, 1211  
Pharmacovigilance, 303  
Phillips, M.G. *see* Pereira, S.P.
- Phuncarg, D.C. *see* Wheeldon, T.-U.  
Piattelli, M. *see* Mangia, A.  
Piche, T. *see* Zerbib, F.  
Piermanni, V. *see* Mangia, A.  
Pilgrim, P. *see* El-Serag, H.B.  
Pilmer, B.L. *see* Freston, J.W.  
Pirozzi, G. *see* Cammarota, G.  
Plein, K. *see* Madisch, A.  
Pola, P. *see* Santarelli, L.  
Pollok, R. *see* Kang, J.Y.  
Poluzzi, E. *see* Tonini, M.  
Polyps, 879  
Poon, R.T.P. *see* Lam, C.-M.  
Poon, R.T.-P., Yu, W.-C., Fan, S.-T. & Wong, J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial, 779  
Poordad, F.F. *see* Firpi, R.J.  
Population Based Study, 1025  
Portal hypertension, 79  
Pouchitis, 281  
Prasad, P. *see* Malik, A.H.  
Prebiotic, 889  
Prescott, R.J. *see* Ho, G.T.  
Primary biliary cirrhosis, 563  
Primary care, 349, 529, 907  
Pritchard, D.M. & Przemeck, S.M.C. Review article: how useful are the rodent animal models of gastric adenocarcinoma? 841  
Proctalgia, 481  
Profound hypochlorhydria, 1181  
Proton pump inhibition, 591  
Proton pump inhibitor(s), 443, 663, 907, 1041, 1051, 1099, 1105  
Pruritus, 1293  
Przemeck, S.M.C. *see* Pritchard, D.M.
- Quality of life, 529, 1099, 1217  
Quality of life assessment, 455  
Quesada, M. *see* Gisbert, J.P.  
Questionnaire, 463
- Rabeprazole, 113  
Raddatz, D., Middel, P., Bockemühl, M., Benöhr, P., Wissmann, C., Schwörer, H. & Ramadori, G. Glucocorticoid receptor expression in inflammatory bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis, 47  
Radiocontrast agent, 999  
Raines, D.L., Dupont, A.W. & Arguedas, M.R. Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding, 571  
Rajendra, S. *see* Kaptan, K.  
Rajendra, S., Alahuddin, S. & Perri, F. Letters to the Editors, 375  
Ramadori, G. *see* Raddatz, D.  
Rampton, D.S. *see* Langmead, L.  
Randomised controlled trial, 349, 889  
Randomised trial, 917

- Rao, S.S.C. *see* Tuteja, A.K.  
 Raskine, L. *see* Bouhnik, Y.  
 Rasmussen, S.N. *see* Nørgård, B.  
 Rautelin, H.I. *see* Koivisto, T.T.  
 Record, C.O. *see* Aithal, G.P.  
 Reflux, 449, 463  
 Reinshagen, M. *see* Herrlinger, K.R.  
 Reiss, G. & Keefe, E.B. Review article: hepatitis vaccination in patients with chronic liver disease, 715  
 Relapse, 671  
 Renal failure, 999  
 Reoperation, 1073  
 Resistance, 789  
 Review, 245  
 Review article, 941  
 Rex, D.K. *see* Chen, S.C.  
 Rey, E. *see* Diaz-Rubio, M.  
 Rheumatoid arthritis, 1189  
 Ribavirin, 551  
 Richards, C.J. *see* Todd, J.A.  
 Riottot, M. *see* Bouhnik, Y.  
 Risk score, 1079  
 Robinson, R.J. *see* Todd, J.A.  
 Rodriguez-Artalejo, F. *see* Diaz-Rubio, M.  
 Rofecoxib, 755  
 Rome II criteria, 1217  
 van Rossum, L.G.M., Laheij, R.J.F., Vlemmix, F., Jansen, J.B.M.J. & Verheugt, F.W.A. Health-related quality of life in patients with cardiovascular disease – the effect of upper gastrointestinal symptom treatment, 1099  
 Rubin, G.P., Hungin, A.P.S., Chinn, D.J. & Dwarakanath, D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey, 529  
 Ruhl, A. *see* Herrlinger, K.R.  
 Russo, A. *see* Borrelli, F.  
 Russo, F. *see* De Francesco, V.  
 Rutgeerts, P. *see* Louis, E.  
 Rutgeerts, P. *see* Marchal, L.  
 Ruzsöcs, A. Molnar B. Tulassay Z. Review article: deoxyribonucleic acid-based diagnostic techniques to detect *Helicobacter pylori*, 1137  
 Ryder, S.D. *see* Austin, A.S.
- Sabusco, G. *see* Angelico, M.  
 Sacher-Huvelin, S. *see* Galmiche, J.P.  
 Saleki, M. *see* Dammann, H.-G.  
 Sampliner, R.E. *see* El-Serag, H.B.  
 Sandborn, W.J., Hanauer, S.B. & Buch, A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers, 1089  
 Sanders, G.D. *see* Lin, O.S.  
 Santarelli, L., Gabrielli, M., Cremonini, F., Santoliquido, A., Candelli, M., Nista, E.C., Pola, P., Gasbarrini, G. & Gasbarrini, A. Atrophic gastritis as a cause of hyperhomocysteinaemia, 107  
 Santoliquido, A. *see* Santarelli, L.  
 Satiety, 1261  
 Satsangi, J. *see* Ho, G.T.  
 Savarino, V. *see* Zentilin, P.  
 Schattenberg, G. *see* Krol, N.  
 Schimansky, T. *see* Kivitz, A.J.  
 Schmidt, B. *see* Hammer, J.  
 Schmidt, H.H.-J. *see* Büning, C.  
 Schoelmerich, J. *see* Herrlinger, K.R.  
 Schoenfeld, P. *see* El-Serag, H.B.  
 Schoenfeld, P. Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials, 263  
 Schröder, O., Blumenstein, I., Schulte-Bockholt, A. & Stein, J. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine, 295  
 Schulte-Bockholt, A. *see* Schröder, O.  
 Schulz, H.-U. *see* Dammann, H.-G.  
 Schürer, M. *see* Dammann, H.-G.  
 Schusdziarra, V. *see* Erdmann, J.  
 Schwab, M. *see* Herrlinger, K.R.  
 Schwabe, M. *see* Treiber, G.  
 Schwartz, D.A. & Herdman, C.R. Review article: the medical treatment of Crohn's perianal fistulas, 953  
 Schwetz, I., Naliboff, B., Munakata, J., Lembo, T., Chang, L., Matin, K., Ohning, G. & Mayer, E.A. Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome, 123  
 Schwizer, W. *see* Fox, M.  
 Schwörer, H. *see* Raddatz, D.  
 Sciveres, M., Caprai, S., Palla, G., Ughi, C. & Maggiore, G. Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents, 209  
 Screening, 571, 1159, 1225  
 Secondary prophylaxis, 571  
 Second-line medical therapy, 1079  
 Sekine, H. *see* Iijima, K.  
 Sepulveda, A. *see* Cremonini, F.  
 Sequential therapy, 407, 993  
 Severe acute pancreatitis, 1153  
 Shackleton, C. *see* Firpi, R.J.  
 Shah, N.B. *see* Ho, G.T.  
 Shand, A.G. *see* Emmanuel, A.V.  
 Shillington, A. *see* Jensen, D.M.  
 Shimatani, T., Inoue, M., Kuroiwa, T. & Horikawa, Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for nighttime gastric acid suppression, 113  
 Shimosegawa, T. *see* Iijima, K.  
 Silk, D.B.A. *see* Castle, M.Z.D.  
 Sinclair, P. *see* Chiba, N.  
 Single Dose PK, 1089  
 Sipponen, P.I. *see* Koivisto, T.T.  
 Sjunnesson, H. *see* Sturegård, E.  
 Somatostatin analogue, 123

- Soncini, M., Triossi, O., Leo, P. & Magni (on behalf of the Ring Study Group). G. Inflammatory bowel disease and hospital treatment in Italy: the RING multi-centre study. 63
- Sonnenberg, A. Personal view: going around in circles — circuitous medical management plans. 191
- Sonnenberg, A. Personal view: patient-physician discordance about benefits and risks in gastroenterology decision-making. 1247
- Sörberg, M. *see* Wheeldon, T.-U.
- Sørensen, H.T. *see* Nørgård, B.
- Spaggiari, P. *see* Zentilin, P.
- Spinzi, G. *see* Mangia, A.
- Sprue, 1199
- Staging, 391
- Stange, E.F. *see* Herrlinger, K.R.
- Stanghellini, V., Armstrong, D., Mönnikes, H. & Bardhan, K.D. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? 463
- Stark, M.E. *see* Ward, E.M.
- Steatosis, 391
- Stein, J. *see* Schröder, O.
- Stern, R.M. *see* Levine, M.E.
- Steroid resistance, 47
- Stolle, J.C. *see* Freston, J.W.
- Stool, 923
- Stoppino, V. *see* De Francesco, V.
- Stroud, M.A. *see* Trebble, T.M.
- Study 031, 1089
- Sturegård, E., Hertervig, E., Sjunnesson, H. & Wadström, T. Letter to the Editors. 613
- Sturniolo, G.C. *see* Di Sabatino, A.
- Stutz, B. *see* Fox, M.
- Surgery, 829, 1079
- Surgical complications, 749
- Surveillance, 303
- Survival, 779, 1301
- Swan, C.H.J. *see* Green, J.R.B.
- Swarbrick, E.T. *see* Green, J.R.B.
- Symptoms, 219, 463
- Systematic Review, 631
- Taccoen, A. *see* Galmiche, J.P.
- Tack, J. *see* Demarchi, B.
- Tack, J. *see* Lee, K.-J.
- Tagore, K.S., Levin, T.R. & Lawson, M.J. Review article: the evolution to stool DNA testing for colorectal cancer. 1225
- Talley, N.J. *see* El-Serag, H.B.
- Talley, N.J. *see* Eslick, G.D.
- Talley, N.J. *see* Halder, S.L.S.
- Talley, N.J. *see* Locke III, G.R.
- Tam, J.S.-L. *see* Wong, V.W.-S.
- Tanaka, S. *see* Kai, H.
- Tarone, R.E. *see* Nørgård, B.
- Tarquini, L. *see* Angelico, M.
- Tegaserod, 263
- Tenatoprazole, 655
- Terpstra, A. *see* Mathus-Vliegen, E.M.H.
- Test and eradicate, 349
- Testa, R. *see* Giannini, E.G.
- Thalidomide, 79
- Third-line, 789
- Thomson, A.B.R. *see* Chiba, N.
- Thorell, L. *see* Collin, P.
- Thornton, P.C. *see* Green, J.R.B.
- Threshold analysis, 1247
- Thumshirn, M. *see* Fox, M.
- Thurston, H.J. *see* Kivitz, A.J.
- Tibbs, C.J. *see* Kang, J.Y.
- Timm, J. *see* Dammann, H.-G.
- Tissue transglutaminase antibody, 1199
- Todd, J.A., Richards, C.J., Dixon, A. & Robinson, R.J. Gastric ulcer and malignancy — is there a need for follow-up endoscopy? 989
- Tome, S. & Lucey, M.R. Review article: current management of alcoholic liver disease. 707
- Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G.R. & De Ponti, F. Review article: clinical implications of enteric and central D<sub>2</sub> receptor blockade by antidopaminergic gastrointestinal prokinetics. 379
- Torz, M. *see* Dammann, H.-G.
- Tosti, A. *see* Angelico, M.
- Tosti, C. *see* Biancone, L.
- Tran, T.T. *see* Firpi, R.J.
- Transarterial, 779
- Transient lower oesophageal sphincter relaxations, 931
- Transplantation, 1033
- Trapero, M. *see* Gisbert, J.P.
- Treatment, 253, 271, 631, 789, 829
- Trebble, T.M., Wootton, S.A., Stroud, M.A., Mullee, M.A., Calder, P.C., Fine, D.R., Moniz, C. & Arden, N.K. Laboratory markers predict bone loss in Crohn's disease: relationship to blood mononuclear cell function and nutritional status. 1063
- Treiber, G., Schwabe, M., Ammon, S., Walker, S., Klotz, U. & Malfertheiner, P. Dyspeptic symptoms associated with *Helicobacter pylori* infection are influenced by strain and host specific factors. 219
- Triossi, O. *see* Soncini, M.
- Triple therapy, 407, 993, 1315
- Tsironi, E. *see* Langmead, L.
- Tulassay, Z. *see* Ruzsovcics, A.
- Tumor necrosis factor- $\alpha$ , 295
- Tumour necrosis factor, 79
- Tuteja, A.K. & Rao, S.S.C. Review article: recent trends in diagnosis and treatment of faecal incontinence. 829
- Tutuian, R., Castell, D.O., Xue, S. & Katz, P.O. The acidity index: a simple approach to the measurement of gastric acidity. 443
- Tuzun, A. *see* Uygün, A.
- Ughi, C. *see* Sciveres, M.
- Ulcerative colitis, 179, 879, 1079
- Ulcers, 1051, 1189



- Umegae, S. *see* Yamamoto, T.  
*Uninvestigated dyspepsia*, 349  
*Upper gastrointestinal bleeding*, 817  
*Upper GI cancer*, 981  
*Utility function*, 1247  
 Uygun, A., Kadayifci, A., Isik, A.T., Ozgurtas, T., Deveci, S., Tuzun, A., Yesilova, Z., Gulsen, M. & Dagalp, K. Metformin in the treatment of patients with non-alcoholic steatohepatitis, 537
- VacA*, 407  
 Vakil, N. Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease, 1041  
 Van Assche, G. *see* Marchal, L.  
 Van Balen, J. *see* Krol, N.  
 Van Gossum, A. *see* Louis, E.  
 Van Haarst, A.D. *see* Kamerling, I.M.C.  
 Van Ierland-Van Leeuwen, M.L. *see* Mathus-Vliegen, E.M.H.  
*Vanilloid receptor*, 415  
 Vavasseur, F. *see* Galmiche, J.P.  
 Veldhuyzen Van Zanten, S.J.O. *see* Abraham, N.S.  
 Veldhuyzen Van Zanten, S.J.O. *see* Chiba, N.  
 Verheugt, F.W.A. *see* van Rossum, L.G.M.  
 Vermeire, S. *see* Louis, E.  
 Vermeire, S. *see* Marchal, L.  
 Vierling, J.M. *see* Firpi, R.J.  
 Vigneri, S. *see* Zentilin, P.  
 Vilien, M. Dahlerup J.F. Munck L.K. Nørregaard P. Grønbaek K. Fallingborg J. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year, 1147  
*Viral resistance*, 25  
*Virologic response*, 551  
*Virological response rate*, 331  
*Vitamin B12*, 107  
 Vlavianos, P. *see* Lindsay, J.O.  
 Vlemmix, F. *see* van Rossum, L.G.M.  
 Vos, R. *see* Demarchi, B.  
 Vos, R. *see* Lee, K.-J.  
 Voutilainen, M.E. *see* Koivisto, T.T.  
 Vuturo, O. *see* Mangia, A.
- Wadström, T. *see* Sturegård, E.  
 Wald, A. *see* Brisinda, G.  
 Wald, A. *see* Cheung, O.  
 Walker, S. *see* Treiber, G.  
 Wang, Q. *see* Freston, J.W.  
 Wang, W.A. *see* Xiong, L.S.  
 Ward, E.M., Devault, K.R., Bouras, E.P., Stark, M.E., Wolfen, H.C., Davis, D.M., Nedrow, S.I. & Achem, S.R. Successful oesophageal pH monitoring with a catheter-free system, 449  
 Watier, H. *see* Louis, E.  
 Wedel, M. *see* Miner Jr, P.  
*Weight loss*, 1173  
 Wensing, M. *see* Krol, N.
- Wenzl, H.H., Hinterleitner, T.A., Aichbichler, B.W., Fickert, P. & Petritsch, W. Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome, 427  
 Westaby, D. *see* Lindsay, J.O.  
 Wheeldon, T.-U., Granström, M., Hoang, T.T.H., Phuncarg, D.C., Nilsson, L.E. & Sörberg, M. The importance of the level of metronidazole resistance for the success of *Helicobacter pylori* eradication, 1315  
 Whorwell, P.J. *see* Calvert, E.L.  
 Williams, R. *see* Pereira, S.P.  
 Williamson, M.J. *see* Levine, M.E.  
*Wilson disease*, 157  
 Winther, K.V. *see* Jess, T.  
 Wissmann, C. *see* Raddatz, D.  
*Withdrawal*, 1147  
 Wolfen, H.C. *see* Ward, E.M.  
 Wollan, P.C. *see* Locke III, G.R.  
 Wong, B.C.Y. *see* Chan, A.O.O.  
 Wong, B.C.Y. *see* Hui, C.-K.  
 Wong, B.C.-Y. *see* Ng, F.-H.  
 Wong, B.C.Y. *see* Wong, W.M.  
 Wong, J. *see* Poon, R.T.-P.  
 Wong, M.L. *see* Wong, V.W.-S.  
 Wong, N.Y.H. *see* Wong, W.M.  
 Wong, S.-Y. *see* Ng, F.-H.  
 Wong, V.W.-S., Chan, H.L.-Y., Wong, M.L., Tam, J.S.-L. & Leung, N.W.-Y. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants 323  
 Wong, W.-M. *see* Hui, C.-K.  
 Wong, W.M., Lai, K.C., Hui, W.M., Lam, K.F., Huang, J.Q., Hu, W.H.C., Wong, N.Y.H., Lam, C.L.K., Xia, H.H.X., Chan, A.O.O., Lam, S.K. & Wong, B.C.Y. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease, 455  
 Wootton, S.A. *see* Trebble, T.M.  
 Wu, J.-C. *see* Huo, T.  
 Wu, J.-C. *see* Huo, T.-I.
- Xia, H.H.X. *see* Wong, W.M.  
 Xiong, L.S., Chen, M.H., Chen, H.X., Xu, A.G., Wang, W.A. & Hu, P.J. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling, 1217  
 Xu, A.G. *see* Xiong, L.S.  
 Xue, S. *see* Tutuian, R.
- Yamamoto, T., Umegae, S., Kitagawa, T. & Matsumoto, K. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse, 671  
 Yawn, B.P. *see* Locke III, G.R.  
 Yesilova, Z. *see* Uygun, A.  
*YMDD mutants*, 323

*Young screening*, 771

Yu, W.-C. *see* Poon, R.T.-P.

Yuen, M.F. *see* Chan, A.O.O.

Yuen, M.-F. *see* Hui, C.-K.

Zaru, S. *see* Angelico, M.

Zentilin, P., Mastracci, L., Dulbecco, P., Gambaro, C., Bilardi, C.,

Ceppa, P., Spaggiari, P., Iiritano, E., Mansi, C., Vigneri, S.,

Fiocca, R. & Savarino, V. Carditis in patients with gastro-oesophageal reflux disease: results of a controlled study based

on both endoscopy and 24-h oesophageal pH monitoring, 1285

Zerbib, F., Piche, T., Charles, F., Galmiche, J.-P. & Bruley des Varannes, S. SR 48692, a specific neurotensin receptor antagonist, has no effect on oesophageal motility in humans, 931

Zinc, 157

Zinsmeister, A.R. *see* Halder, S.L.S.

Zullo, A. *see* De Francesco, V.



